摘要
到目前为止,开发用于细胞内应用的治疗肽的努力受到未修饰的线性肽高度不稳定的认识的指导,因此需要进行结构修饰以减少蛋白水解分解。大多数情况下,这个概念是迄今为止关于细胞内肽的大多数研究集中在抗原加工背景下的肽降解而不是肽稳定性的事实。有趣的是,在细胞内,缺乏任何化学修饰以增强稳定性的内源肽逃避降解,甚至可能调节细胞内信号通路。此外,许多未修饰的合成肽被设计成干扰细胞内信号传导,在引入细胞后,具有预期的活性,表明可以达到生物相关的浓度。本综述概述了与线性未修饰肽的探索和应用相关的结果和技术。引入细胞内肽周转后,综述提及合成肽作为细胞内信号传导调节剂的实例
关键词: 合成肽,细胞内肽,生物活性内源肽,肽稳定性,细胞内信号传导,肽递送。
Current Medicinal Chemistry
Title:Linear Peptides in Intracellular Applications
Volume: 24 Issue: 17
关键词: 合成肽,细胞内肽,生物活性内源肽,肽稳定性,细胞内信号传导,肽递送。
摘要: To this point, efforts to develop therapeutic peptides for intracellular applications were guided by the perception that unmodified linear peptides are highly unstable and therefore structural modifications are required to reduce proteolytic breakdown. Largely, this concept is a consequence of the fact that most research on intracellular peptides hitherto has focused on peptide degradation in the context of antigen processing, rather than on peptide stability. Interestingly, inside cells, endogenous peptides lacking any chemical modifications to enhance stability escape degradation to the point that they may even modulate intracellular signaling pathways. In addition, many unmodified synthetic peptides designed to interfere with intracellular signaling, following introduction into cells, have the expected activity demonstrating that biologically relevant concentrations can be reached. This review provides an overview of results and techniques relating to the exploration and application of linear, unmodified peptides. After an introduction to intracellular peptide turnover, the review mentions examples for synthetic peptides as modulators of intracellular signaling, introduces endogenous peptides with bioactivity, techniques to measure peptide stability, and peptide delivery. Future experiments should elucidate the rules needed to predict promising peptide candidates.
Export Options
About this article
Cite this article as:
Linear Peptides in Intracellular Applications, Current Medicinal Chemistry 2017; 24 (17) . https://dx.doi.org/10.2174/0929867324666170508143523
DOI https://dx.doi.org/10.2174/0929867324666170508143523 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards Improved Therapies Using Nanopharmaceuticals: Recent Patents on Pharmaceutical Nanoformulations
Recent Patents on Food, Nutrition & Agriculture Antibody Library Display on a Mammalian Virus Vector: Combining the Advantages of Both Phage and Yeast Display into One Technology
Current Drug Discovery Technologies Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Recent Developments of Phototherapy Based on Graphene Family Nanomaterials
Current Medicinal Chemistry Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy Regulation of Heat Shock Proteins by miRNAs in Human Breast Cancer
MicroRNA Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Snake Venom: From Deadly Toxins to Life-saving Therapeutics
Current Medicinal Chemistry A Novel Method to Synthesize 4-Aryl-1H-1,2,3-Triazoles and its Antihepatoma Activity
Anti-Cancer Agents in Medicinal Chemistry Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Equol is Neuroprotective During Focal Cerebral Ischemia and Reperfusion that Involves p-Src and gp91<sup>phox</sup>
Current Neurovascular Research Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women
Mini-Reviews in Medicinal Chemistry Synthesis of New A-CD Estrogenic Compounds: D-Homo-analogs Lacking B-ring
Current Organic Chemistry The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making
Current Medicinal Chemistry Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry